Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.
In a sub-analysis of the ARIC study, midlife systemic inflammation was associated with the development of chronic microangiopathic structural white matter abnormalities in the elderly.
AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.
AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.
This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.
Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.
Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.
A year of treatment with low-dose colchicine significantly lowered low attenuation plaque volume and hsCRP levels, as compared with optimal medical treatment in patients with recent ACS.
Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.
Inflammation Expert Opinions Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.
This summary by Prof Ray gives insight in the high CV risk in patiens with diabetes. Treatment options and testing of these drugs in trials were discussed, including the new antidiabetic drugs, such as empagliflozin, and other novel agents, such as the PCSK9 inhibitor evolocumab.
Pooled analysis of phase II studies evaluating apabetalone suggest that this epigenetic therapeutic may yield clinical benefit for CVD patients with low HDL-C, diabetes, and elevated hsCRP levels.